Filtered By:
Therapy: Hormonal Therapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 218 results found since Jan 2013.
Endocrine disorders in a patient with a suspicion of a mitochondrial disease, MELAS syndrome - a case report and literature review
We present a girl who was suspected of MELAS syndrome during the diagnostic evaluation of short stature. The patient suffered from symptoms potentially indicating mitochondrial disease, such as muscular weakness, cranial nerve VI palsy, headaches, retinitis pigmentosa, sensory-neural hearing loss, and elevated lactic acid. T2-weighted brain MRI showed hyperintense lesions in the white matter. Muscular biopsy revealed ragged red fibres. Genetic evaluation did not detect the most common mutations in the MT-TL1 gene and MT-ND5 gene. Endocrine tests led to the confirmation of growth hormone deficiency, and so replacement treat...
Source: Pediatric Endocrinology, Diabetes, and Metabolism - October 1, 2021 Category: Endocrinology Authors: Marta Baszy ńska-Wilk El żbieta Moszczyńska Maria Szarras-Czapnik Marta Wysocka-Mincewicz Urszula W ątrobińska Agata Koz łowska Mieczys ław Szalecki Source Type: research
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
AbstractBACKGROUNDMenopausal symptoms can be very distressing and considerably affect a woman ’s personal and social life. It is becoming more and more evident that leaving bothersome symptoms untreated in midlife may lead to altered quality of life, reduced work productivity and, possibly, overall impaired health. Hormone therapy (HT) for the relief of menopausal symptoms has been the obj ect of much controversy over the past two decades. At the beginning of the century, a shadow was cast on the use of HT owing to the concern for cardiovascular and cerebrovascular risks, and breast cancer, arising following publication ...
Source: Human Reproduction Update - August 25, 2021 Category: OBGYN Source Type: research
Thyroid Hormone Therapy and Incident Stroke
CONCLUSIONS: Both exogenous hyper- and hypothyroidism were associated with increased risk of stroke, highlighting the importance of patient medication safety.PMID:34137866 | DOI:10.1210/clinem/dgab444
Source: The Journal of Clinical Endocrinology and Metabolism - June 17, 2021 Category: Endocrinology Authors: Maria Papaleontiou Deborah A Levine David Reyes-Gastelum Sarah T Hawley Mousumi Banerjee Megan R Haymart Source Type: research
The role of medications in successful aging
Climacteric. 2021 May 12:1-8. doi: 10.1080/13697137.2021.1911991. Online ahead of print.ABSTRACTSuccessful aging includes good health and low levels of disability. To that end, primary prevention is far better than managing subsequent organ damage. When medication is needed to prevent or manage disease, the preferred choice should be associated with the greatest benefits and fewest adverse effects. Cardiovascular diseases are the leading cause of morbidity and mortality in postmenopausal women worldwide. Considering disease-adjusted life years, other leading causes are chronic obstructive pulmonary disease, diabetes mellit...
Source: Climacteric - May 12, 2021 Category: Geriatrics Authors: R D Langer Source Type: research
Current Perspective on Menopause Hormone Therapy and Cardiovascular Risk
AbstractPurpose of reviewIn past decades, there has a been a paradigm shift concerning menopause, hormone therapy (HT), and cardiovascular disease (CVD). While initial observational studies suggested hormone replacement to provide a cardioprotective benefit for all menopausal women, subsequent large randomized trials have not confirmed these benefits and furthermore brought to light the risks of HT with regard to CVD, venous thrombosis, and stroke. The goal of this review is to summarize current recommendations regarding HT as it pertains to cardiovascular risk.Recent FindingsMenopause HT remains the most effective treatme...
Source: Current Treatment Options in Cardiovascular Medicine - May 5, 2021 Category: Cardiology Source Type: research
Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones
(American Heart Association) Patients with breast and prostate cancers who are treated with hormonal therapies have an increased risk of heart attack and/or stroke as they age.The increased likelihood of a heart attack or stroke is greater in patients who already have two or more cardiovascular risk factors such as high blood pressure, high cholesterol, obesity, smoking or a family history of heart disease or stroke.The longer the duration of hormonal therapy, the higher the risk of cardiovascular disease.
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news
Assessment of Cardiovascular Risk in Transgender Patients Presenting for Gender-Affirming Care
The transgender population is rapidly growing in the United States and abroad. Transgender men and women are marginalized as a result of their transgender status with resultant health repercussions. This and other factors such as increased substance use, mental health disorders, violence, and chronic stress may place transgender individuals at higher risk for cardiovascular disease. Additionally, many transgender patients pursue gender affirming hormone therapy which has been linked to increased rates of some cardiovascular events such as metabolic syndrome, venous thromboembolism, and stroke.
Source: The American Journal of Medicine - April 22, 2021 Category: General Medicine Authors: Kara J. Denby, Leslie Cho, Karlo Toljan, Meghana Patil, Cecile A. Ferrando Source Type: research
The effect of female sex hormones on Hsp27 phosphorylation and histological changes in prefrontal cortex after tMCAO
CONCLUSION: Our results indicate that the neuroprotective effect of neurosteroids in the brain may be due to the modulation of heat shock proteins.PMID:33857717 | DOI:10.1016/j.prp.2021.153415
Source: Pathology, Research and Practice - April 15, 2021 Category: Pathology Authors: Zeinab Vahidinia Elham Mahdavi Sayyed Alireza Talaei Homayoun Naderian Aboutaleb Tamtaji Hamed Haddad Kashani Cordian Beyer Abolfazl Azami Tameh Source Type: research
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Expert Opin Investig Drugs. 2021 Mar 16. doi: 10.1080/13543784.2021.1893305. Online ahead of print.ABSTRACTINTRODUCTION: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of vasomotor symptoms (...
Source: Expert Opinion on Investigational Drugs - March 16, 2021 Category: Drugs & Pharmacology Authors: Herman Depypere Christopher Lademacher Emad Siddiqui Graeme L Fraser Source Type: research
